Literature DB >> 27562033

Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients.

Natasa Stanisavljevic1, L Stojanovich2, D Marisavljevic2,3, A Djokovic2,3, V Dopsaj4, J Kotur-Stevuljevic5, J Martinovic6, L Memon2, S Radovanovic2, B Todic2, D Lisulov2.   

Abstract

The aim of this study was to evaluate oxidative stress markers and it relations to endothelial damage as risk factor for thrombosis in patients with primary (PAPS) and secondary (SAPS) antiphospholipid syndrome (APS) in correlation to traditional risk factors. Flow-mediated (FMD) and nitroglycerine (NMD)-induced dilation of the brachial artery were studied in 140 APS patients (90 PAPS, 50 SAPS) and 40 controls matched by age, sex, and conventional risk factors for atherosclerosis. Markers of oxidative stress, lipid hydroperoxydes (LOOH), advanced oxidation protein products (AOPP), total sulfhydryl groups (tSHG), and paraoxonase 1 activity (PON1) were determined by spectrophotometric method. Oxidative stress dominates in APS patients. LOOH and AOPP correlate to lipid fractions (p < 0.05), unlike PON1, tSHG that correlated to antiphospholipid antibody positivity (p < 0.05). FMD was lower in APS patients comparing to controls (p < 0.001). Cholesterol is independent variable for FMD impairment in control group (p = 0.011); LOOH in PAPS (p = 0.004); LOOH, aCL, and triglycerides in SAPS patients (p = 0.009, p = 0.049, and p = 0.012, respectively). Combined predictive of aCL and LOOH is better for FMD impairment than LOOH alone in both PAPS and SAPS patients (AUC 0.727, p = 0.001, 95 % CI 0.616-0.837 and AUC 0.824, p˂0.001, 95 % CI 0.690-0.957, respectively). Lipid peroxidation is independent predictor for endothelial dysfunction in APS patients. We demonstrated synergistic effect of aCL and LOOH as risk for endothelial impairment in both PAPS and SAPS patients.

Entities:  

Keywords:  Antiphospholipid syndrome; Endothelial dysfunction; Oxidative stress; Thrombosis

Mesh:

Substances:

Year:  2016        PMID: 27562033     DOI: 10.1007/s10067-016-3369-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  43 in total

1.  Serum oxidant/antioxidant status of patients with systemic lupus erythematosus.

Authors:  Seyithan Taysi; Mustafa Gul; Refik Ali Sari; Fatih Akcay; Nuri Bakan
Journal:  Clin Chem Lab Med       Date:  2002-07       Impact factor: 3.694

2.  Endothelial function is impaired in patients with primary antiphospholipid syndrome.

Authors:  Monika Stalc; Pavel Poredos; Polona Peternel; Matija Tomsic; Miran Sebestjen; Tanja Kveder
Journal:  Thromb Res       Date:  2005-11-07       Impact factor: 3.944

3.  Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  J Delgado Alves; P R J Ames; S Donohue; L Stanyer; J Nourooz-Zadeh; C Ravirajan; D A Isenberg; J Noorouz-Zadeh
Journal:  Arthritis Rheum       Date:  2002-10

4.  Impaired antioxidant status and decreased dietary intake of antioxidants in patients with systemic lupus erythematosus.

Authors:  Sang-Cheol Bae; Soo-Jin Kim; Mi-Kyung Sung
Journal:  Rheumatol Int       Date:  2002-09-06       Impact factor: 2.631

5.  Clinical relevance of nitric oxide metabolites and nitrative stress in thrombotic primary antiphospholipid syndrome.

Authors:  Paul R J Ames; Joana R Batuca; Antonio Ciampa; Luigi Iannaccone; Jose Delgado Alves
Journal:  J Rheumatol       Date:  2010-10-01       Impact factor: 4.666

6.  Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus.

Authors:  Philip E Morgan; Allan D Sturgess; Michael J Davies
Journal:  Arthritis Rheum       Date:  2005-07

7.  Cardiovascular risk in systemic lupus erythematosus--evidence of increased oxidative stress and dyslipidaemia.

Authors:  S L Nuttall; S Heaton; M K Piper; U Martin; C Gordon
Journal:  Rheumatology (Oxford)       Date:  2003-02-28       Impact factor: 7.580

8.  Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.

Authors:  D S Celermajer; K E Sorensen; V M Gooch; D J Spiegelhalter; O I Miller; I D Sullivan; J K Lloyd; J E Deanfield
Journal:  Lancet       Date:  1992-11-07       Impact factor: 79.321

9.  The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević; Ljudmila Stojanović; Svetlana Ignjatović; Violeta Dopsaj
Journal:  Clin Rheumatol       Date:  2016-03-14       Impact factor: 2.980

10.  Increased levels of autoantibodies against catalase and superoxide dismutase associated with oxidative stress in patients with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  R Ben Mansour; S Lassoued; B Gargouri; A El Gaïd; H Attia; F Fakhfakh
Journal:  Scand J Rheumatol       Date:  2008 Mar-Apr       Impact factor: 3.641

View more
  4 in total

Review 1.  Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?

Authors:  Salma Siddique; Jessie Risse; Guillaume Canaud; Stéphane Zuily
Journal:  Curr Rheumatol Rep       Date:  2017-09-04       Impact factor: 4.592

2.  COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs? (2017 Grover Conference Series).

Authors:  Francesca Polverino; Bartolome R Celli; Caroline A Owen
Journal:  Pulm Circ       Date:  2018 Jan-Mar       Impact factor: 3.017

3.  Correlation of Paraoxonase-1 with the Severity of Crohn's Disease.

Authors:  Katarzyna Szczeklik; Tomasz Mach; Dorota Cibor; Danuta Owczarek; Jacek Sapa; Monika Papież; Jolanta Pytko-Polończyk; Wirginia Krzyściak
Journal:  Molecules       Date:  2018-10-11       Impact factor: 4.411

4.  Association between plasmatic oxidative stress and thrombosis in primary antiphospholipid syndrome.

Authors:  Camila O Vaz; Bruna M Mazetto; Pedro Eduardo N S Vasconcelos; Larissa B Bastos; Maria Aparecida Cursino; Júlia Coelho França Quintanilha; Gabriela Lisiane Tripiquia Vechiatto Mesquita; Ana Paula R Santos; Bruna Cardoso Jacintho; José Diogo Oliveira; Joyce Annichino-Bizzachi; Fernanda A Orsi
Journal:  J Thromb Thrombolysis       Date:  2021-07-05       Impact factor: 2.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.